6090 — Human Metabolome Technologies Share Price
0.000.00%
Last trade - 00:00- ¥4bn
- ¥3bn
- ¥1bn
- 43
- 46
- 77
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.12 | ||
| Price to Tang. Book | 2.14 | ||
| Price to Free Cashflow | 12.73 | ||
| Price to Sales | 2.93 | ||
| EV to EBITDA | 7.27 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.4% | ||
| Return on Equity | 14.36% | ||
| Operating Margin | 20.06% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 1,118.49 | 1,124.07 | 1,223.28 | 1,299.22 | 1,345.67 | n/a | n/a | 6.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +311.09 | +7.87 | -20.84 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Human Metabolome Technologies, Inc. is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions. The Company operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.
Directors
- Ryuji Kanno CHM (71)
- Katsuhito Hashizune PRE (51)
- Naotaka Kametani DSL
- Masatoshi Nakamura DSL
- Yoshiaki Ohashi EXO (46)
- Tomomi Ishihara EXO
- Kenjiro Kami EXO
- Jun Nagashima EXO (44)
- Yuji Suzuki EXO (39)
- Hideaki Murakami OTH (41)
- Toshiyasu Miyazaki DRC
- Junichi Matsuda IND
- Midori Mizutani IND (41)
- Toshio Nagae IND (77)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 1st, 2003
- Public Since
- December 24th, 2013
- No. of Shareholders
- 4,572
- No. of Employees
- 58
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 5,919,653
- Address
- 246-2, Mizukami, Kakuganji, TSURUOKA-SHI, 997-0052
- Web
- https://humanmetabolome.com/
- Phone
- +81 235251447
- Auditors
- Shinsoh Audit Corporation
Upcoming Events for 6090
Dividend For 6090.T - 15.0000 JPY
Similar to 6090
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the Human Metabolome Technologies share price?
As of Today at 21:10 UTC, shares in Human Metabolome Technologies are trading at ¥691. This share price information is delayed by 15 minutes.
How has the Human Metabolome Technologies share price performed this year?
Shares in Human Metabolome Technologies last closed at ¥691 and the price had moved by +4.38% over the past 365 days. In terms of relative price strength the Human Metabolome Technologies share price has outperformed the Nikkei 225 Index by +10% over the past year.
What are the analyst and broker recommendations for Human Metabolome Technologies?
There is no consensus recommendation for this security.
Find out moreWhat is the Human Metabolome Technologies dividend yield?
The Human Metabolome Technologies dividend yield is 2.17% based on the trailing twelve month period.
Does Human Metabolome Technologies pay a dividend?
Last year, Human Metabolome Technologies paid a total dividend of ¥15, and it currently has a trailing dividend yield of 2.17%.Looking ahead, shares in Human Metabolome Technologies are due to go ex-dividend on 2025-06-27 and the next dividend pay date is 2025-09-01.
When does Human Metabolome Technologies next pay dividends?
Human Metabolome Technologies are due to go ex-dividend on 2025-06-27 and the next dividend pay date is 2025-09-01. The historic dividend yield on Human Metabolome Technologies shares is currently 2.17%.
How do I buy Human Metabolome Technologies shares?
To buy shares in Human Metabolome Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Human Metabolome Technologies?
As of the previous close price of ¥691, shares in Human Metabolome Technologies had a market capitalisation of ¥4bn.
Where are Human Metabolome Technologies shares listed?
Here are the trading details for Human Metabolome Technologies:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 6090
What kind of share is Human Metabolome Technologies?
Based on an overall assessment of its quality, value and momentum Human Metabolome Technologies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Human Metabolome Technologies share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Human Metabolome Technologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Human Metabolome Technologies. Over the past six months, its share price has outperformed the Nikkei 225 Index by +32.23%.
As of the last closing price of ¥691, shares in Human Metabolome Technologies were trading +9.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Human Metabolome Technologies PE Ratio?
The Human Metabolome Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥691.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Human Metabolome Technologies?
Human Metabolome Technologies' management team is headed by:
- Ryuji Kanno - CHM
- Katsuhito Hashizune - PRE
- Naotaka Kametani - DSL
- Masatoshi Nakamura - DSL
- Yoshiaki Ohashi - EXO
- Tomomi Ishihara - EXO
- Kenjiro Kami - EXO
- Jun Nagashima - EXO
- Yuji Suzuki - EXO
- Hideaki Murakami - OTH
- Toshiyasu Miyazaki - DRC
- Junichi Matsuda - IND
- Midori Mizutani - IND
- Toshio Nagae - IND